These press releases are for business and financial media.
-
- 28 December 2005
- AstraZeneca Signs Collaboration Agreement with Targacept for New Neuronal Nicotinic Receptor Compounds Phase II compound for improving cognitive deficits in Alzheimer’s Disease and Schizophrenia included in agreement. AstraZeneca today announced that it has signed an exclusive global licensing and research collaboration agreement with Targacept Inc. for the development and commercialization of Targacept's phase II compound, TC-1734 to treat Alzheimer's disease, cognitive deficits in schizophrenia and other cognitive disorders. The four-year research collaboration also allows for the development of other
-
- 23 December 2005
- Acquisition Of KuDOS Pharmaceuticals Will Enhance AstraZeneca’s Ability To Generate Novel Cancer Treatments AstraZeneca today announced an agreement to acquire KuDOS Pharmaceuticals Limited, a privately-owned UK biotechnology company, focused on the discovery and development of oncology therapies based on the inhibition of DNA repair. The total share capital of the company will be purchased for $210m cash, subject to debt and working capital adjustment. The transaction is expected to close early in 2006.
-
- 22 December 2005
- AstraZeneca and AtheroGenics Announce Late Stage Licensing and Commercialisation Agreement for Novel Atherosclerosis Drug AGI-1067 AstraZeneca today announced that it has entered into a licensing deal with AtheroGenics, Inc. (Nasdaq: AGIX) for the global development and commercialisation of their anti-inflammatory cardiovascular product candidate, AGI-1067. AGI-1067 is an investigational oral drug for the treatment of atherosclerosis, the underlying disease process that leads to heart attacks and strokes and is currently in Phase III development in the ARISE (Aggressive Reduction of Inflammation Stops Events) trial.
-
- 14 December 2005
- EU Committee for Orphan Medicinal Products Recommends Orphan Drug Designation for ZD6474 (ZACTIMA™) for the Investigation of a Rare form of Thyroid Cancer AstraZeneca announced today that it has received positive opinion from the Committee for Orphan Medicinal Products (COMP) recommending orphan drug designation for ZD6474 (ZACTIMA™) for the treatment of patients with medullary thyroid cancer in the European Union (EU). Final adoption of the opinion is expected from the European Commission in early 2006.
-
- 09 December 2005
- Data Show Survival Benefit For Arimidex™ In Early Breast Cancer Data presented today at the San Antonio Breast Cancer Symposium (SABCS), Texas has found that 'Arimidex' (anastrozole) is the first aromatase inhibitor (AI) to provide an overall survival benefit, compared with tamoxifen, in the treatment of hormone-sensitive early breast cancer.
-
- 08 December 2005
- AstraZeneca and Protherics Announce Late Stage Licensing Agreement On CytoFab™ AstraZeneca today announced a global development and commercialisation agreement for Protherics anti-sepsis product CytoFab™. CytoFab™ is currently being prepared for a single phase III registration study in severe sepsis in line with guidance received at an end of phase II meeting with the US Food and Drug Administration (FDA).
-
- 22 November 2005
- AstraZeneca Commences Patent Infringement Litigation Against Ranbaxy Laboratories AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Ranbaxy Laboratories for willful infringement of AstraZeneca’s patents protecting NEXIUM® (esomeprazole magnesium).
-
- 17 November 2005
- SYMBICORT® MAINTENANCE AND RELIEVER THERAPY™ IS HIGHLY EFFECTIVE COMPARED WITH ANY DOSE OF SERETIDE™ 17th November 2005. Lund, Sweden. New clinical trial data, published today in the European Respiratory Journal (ERJ)[1], reveals that AstraZeneca’s novel treatment concept - SYMBICORT® Maintenance And Reliever Therapy™ - is highly effective compared with Seretide™ (fluticasone/ salmeterol). The study also provides further evidence that a treatment regimen using just one inhaler for patients day-to-day needs, maintenance and relief, is at least as effective in a real world setting to multiple inhaler
-
- 15 November 2005
- NEW AZD6140 PHASE IIb DATA PRESENTED AT AMERICAN HEART ASSOCIATION Dallas, TXNovember 15, 2005 New Phase IIb data from the DISPERSE2 Study 1 presented today at the American Heart Association Meeting, assessed the safety, tolerability and preliminary efficacy of AstraZeneca’s AZD6140 plus aspirin compared to clopidogrel plus aspirin in patients with non-ST elevation acute coronary syndrome (NSTE-ACS).
-
- 09 November 2005
- AstraZeneca Commences Patent Infringement Litigation Against Teva AstraZeneca announced today that it has filed a lawsuit in the United States District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals Industries, Ltd. for willful infringement of AstraZeneca’s substance patent protecting Seroquel.
-
- 31 October 2005
- FDA Grants ZD6474 (Zactima™) Orphan Drug Designation For The Investigation Of Rare Forms Of Thyroid Cancer AstraZeneca announced today that the US Food and Drug Administration (FDA) has granted ZD6474 (ZACTIMA™) Orphan Drug designation for the treatment of patients with follicular, medullary, anaplastic, and locally advanced and metastatic papillary thyroid cancer. ZD6474 is a unique once-daily oral therapy that selectively targets key cell signalling pathways involved in tumour growth and spread including VEGF (Vascular endothelial growth factor) receptor signalling and EGF (Epidermal growth factor) receptor
-
- 27 October 2005
- THIRD QUARTER AND NINE MONTHS RESULTS 2005 AstraZeneca PLC Third Quarter and Nine Months Results 2005
-
- 18 October 2005
- NEXIUM ANDA AstraZeneca has received a notice from Ranbaxy Pharmaceuticals Inc. that Ranbaxy Laboratories Limited has submitted an Abbreviated New Drug Application (ANDA) for esomeprazole magnesium delayed-release capsules, 20mg and 40mg, containing Paragraph IV Certifications of invalidity and/or non-infringement with respect to certain AstraZeneca US patents listed in the Orange Book in reference to Nexium, the latter of which expires in 2018.
-
- 28 September 2005
- SEROQUEL ANDA
-
- 23 September 2005
- ASTRAZENECA SUBMITS NEW DRUG APPLICATION (NDA) TO FDA FOR SYMBICORT® MAINTENANCE TREATMENT OF ASTHMA AstraZeneca has announced submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for approval of SYMBICORT® (budesonide/formoterol) for the maintenance treatment of asthma.
-
- 15 September 2005
- ASTRAZENECA APPOINTS TONY ZOOK AS EXECUTIVE VICE PRESIDENT for NORTH AMERICA AstraZeneca today announced the appointment of Tony Zook as Executive Vice President for North America, and President and Chief Executive Officer of AstraZeneca US, effective from January 1, 2006.
-
- 07 September 2005
- AZD6140 phase IIa data demonstrate greater and more consistent inhibition of platelet aggregation (IPA) compared with current ‘gold standard’ treatment ESC 2005 Press Release AZD6140.
-
- 06 September 2005
- ESC 2005 - First patient study demonstrates efficacy and safety of AZD7009 European Society of Cardiology (ESC), Stockholm, Tuesday 6 September 2005: Phase II results of its first patient study show that AZD7009 iv, an antiarrhythmic drug in development for the treatment of patients with atrial fibrillation (AF), is effective and well tolerated in restoring sinus rhythm. 1 In this study, 122 patients were randomised for treatment to seven different concentrations (doses) of AZD7009 or placebo. 35 patients received one of the three highest doses and of these 19 (70%) were restored
-
- 28 July 2005
- SECOND QUARTER RESULTS 2005 "Record sales and operating profit in the first half year: year end targets increased."
-
- 28 July 2005
- ASTRAZENECA PLC The Board of AstraZeneca PLC announces the appointment of David R Brennan as Chief Executive with effect from 1 January 2006 upon the retirement at that time of Sir Tom McKillop.
-
- 27 July 2005
- ASTRAZENECA AND SCHERING AG ANNOUNCE COLLABORATION AND LICENSING AGREEMENT IN THE AREA OF ANTI-INFLAMMATORY AGENTS AstraZeneca and Schering AG, Germany, today announced that they have entered into a research collaboration and licensing agreement in the area of Selective Glucocorticoid Receptor Agonists (SEGRAs) which represent a new class of anti-inflammatory agents.
-
- 27 July 2005
- ASTRAZENECA AND ASTEX ANNOUNCE NEW ANTI-CANCER DRUG DISCOVERY ALLIANCE AstraZeneca and Astex Therapeutics Limited today announced a new alliance to discover, develop and commercialise novel small molecule inhibitors of Protein Kinase B (PKB; also known as Akt) for use as anti-cancer agents.
-
- 11 July 2005
- ASTRAZENECA AND AVANIR ANNOUNCE GLOBAL ALLIANCE TO DISCOVER AND DEVELOP NOVEL REVERSE CHOLESTEROL TRANSPORT ENHANCING COMPOUNDS AstraZeneca today announced an exclusive global licensing and research collaboration agreement with Avanir to discover, develop and commercialise Reverse Cholesterol Transport (RCT) enhancing compounds for the treatment of cardiovascular disease.
-
- 04 July 2005
- ASTRAZENECA TO START PHASE III TRIALS WITH ZACTIMA TM (ZD6474) – A NOVEL TARGETED LUNG CANCER TREATMENT AstraZeneca announced today that it is to progress to Phase III studies with its novel oncology compound ZD6474 – now to be known by its trade name, ZACTIMA TM . Recruitment to Phase III studies evaluating the anti-tumour activity of ZACTIMA TM in non-small cell lung cancer (NSCLC) will begin in the next few months.
-
- 01 July 2005
- ASTRA TECH EXPANDS THROUGH DENTAL BUSINESS ACQUISITION Medical device company Astra Tech AB, a subsidiary of AstraZeneca PLC, is acquiring Cresco Ti Systems from its primary owners SEB Företagsinvest, Credit Suisse Innoventure Capital AG, and Banque Cantonale Vaudoise. The deal represents less than one per cent of AstraZeneca’s net assets.
-
- 28 June 2005
- ASTRAZENECA'S BREAST CANCER TREATMENT ARIMIDEX® GRANTED NEW INDICATION ENABLING WIDER ACCESS FOR POSTMENOPAUSAL WOMEN AstraZeneca today announced that 'Arimidex' (anastrozole) has been granted a new indication from the Medicines and Healthcare products Regulatory Agency (MHRA) in the United Kingdom, which has acted as the Reference Member State for the European Mutual Recognition Variation Procedure leading to further approvals in five other European countries - Austria, Germany, Italy, Portugal and Spain.
-
- 15 June 2005
- ASTRAZENECA REFUTES EC’S FINDINGS IN LOSEC DOMINANCE CASE AND APPEALS DECISION AstraZeneca announced today that it does not accept the European Commission’s decision that it infringed Article 82 EC during the marketing of Losec (omeprazole) in the 1990s, and will appeal the decision to fine the company 60 million Euros to the Courts.
-
- 02 June 2005
- Heart failure patients perceive improvement in symptoms on Atacand® treatment1 Mölndal 2 June 2005: A new analysis of the CHARM (Candesartan in Heart Failure - Assessment of Reduction in Mortality and Morbidity) study data published today in the European Journal of Heart Failure 1 shows that patients treated with Atacand ® (candesartan cilexetil), a selective angiotensin receptor blocker (ARB), perceived greater improvement in their heart failure symptoms compared to those on placebo.
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 20-Nov-2009 22:46 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
